(NYSE: AZN) today announced results from a PLATO sub-analysis that evaluated the effect of smoking status on clinical outcomes in patients with acute coronary syndrome (ACS). This analysis suggests the overall findings from the PLATO study of greater reduction in thrombotic CV events with BRILINTA
(ticagrelor) tablets plus aspirin compared to clopidogrel plus aspirin was consistent regardless of smoking habits.
These data, slated for publication in the September issue of
American Heart Journal
, are currently available
, and were previously presented at the American College of Cardiology 2012 meeting.
“The potential impact of smoking on the effect of certain medications continues to be a topic of considerable interest and discussion among the cardiovascular community,” stated James Ferguson, MD, Executive Director, Medical Affairs and Strategic Development, and Vice President for Global Medical Affairs. “This sub-analysis suggests that the clinical benefits of BRILINTA vs clopidogrel on thrombotic CV events shown in PLATO were not significantly affected by smoking status, and were similar in both smokers and non-smokers.”
BRILINTA is indicated to reduce the rate of thrombotic CV events in patients with acute coronary syndrome (ACS: unstable angina [UA], non–ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). In PLATO, BRILINTA has been shown to reduce the rate of a combined end point of CV death, myocardial infarction (MI), or stroke compared to clopidogrel. In PLATO, the difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with an artery-opening procedure known as percutaneous coronary intervention (PCI), BRILINTA reduces the rate of stent thrombosis.
BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin above 100 mg daily.